State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer's disease

Harald Hampel, Leslie M. Shaw, Paul Aisen, Christopher Chen, Alberto Lleó, Takeshi Iwatsubo, Atsushi Iwata, Masahito Yamada, Takeshi Ikeuchi, Jianping Jia, Huali Wang, Charlotte E. Teunissen, Elaine Peskind, Kaj Blennow, Jeffrey Cummings, Andrea Vergallo

Research output: Contribution to journalReview articleAcademicpeer-review

35 Citations (Scopus)


Recent advances in developing disease-modifying therapies (DMT) for Alzheimer's disease (AD), and the recognition that AD pathophysiology emerges decades before clinical symptoms, necessitate a paradigm shift of health-care systems toward biomarker-guided early detection, diagnosis, and therapeutic decision-making. Appropriate incorporation of cerebrospinal fluid biomarker analysis in clinical practice is an essential step toward system readiness for accommodating the demand of AD diagnosis and proper use of DMTs—once they become available. However, the use of lumbar puncture (LP) in individuals with suspected neurodegenerative diseases such as AD is inconsistent, and the perception of its utility and safety differs considerably among medical specialties as well as among regions and countries. This review describes the state-of-the-art evidence concerning the safety profile of LP in older adults, discusses the risk factors for LP-associated adverse events, and provides recommendations and an outlook for optimized use and global implementation of LP in individuals with suspected AD.
Original languageEnglish
JournalAlzheimer's and Dementia
Early online date2021
Publication statusE-pub ahead of print - 2021


  • Alzheimer's disease
  • biomarker
  • cerebrospinal fluid
  • diagnosis
  • evidence-based guidelines
  • lumbar puncture
  • system readiness

Cite this